Prevention & lipidsMeta-analysis
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis
- Participant-level meta-analysis of placebo-controlled statin trials
Authors' conclusion
These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.
Study context
- Population
- Participants enrolled in 6 placebo-controlled statin trials
- Participants
- 27,658 participants · 6 statin trials
- Comparison
- Lp >50 mg/dL vs ≤50 mg/dL, by low-density lipoprotein cholesterol (LDL-C) level
- Outcome
- ASCVD (fatal or nonfatal CHD events, stroke, or any coronary or carotid revascularization)
Pooled result
As reported in the abstract
ASCVD risk by Lp(a) and achieved LDL-C (statin-treated)
Lp(a) >50 mg/dL vs Lp(a) ≤50 mg/dLHazard ratio (95% CI)
lowest quartile of achieved LDL-C (3.1-77.0 mg/dL)
1.38(1.06–1.79)
with LDL-C in fourth quartile; greatest risk
1.90(1.46–2.48)
Original publication
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. Published 4 November 2024. doi:10.1161/circulationaha.124.069556
Summarised from the published abstract; every number is checked against it